Key result
High peripheral monocytes predict ~124% more heart failure events in non-HFpEF but not HFpEF patients.
Why the study?
Pathophysiological conditions differ between HFpEF and non-HFpEF, prompting an evaluation of the prognostic value of peripheral monocyte counts for future HF-related events in patients with HF.
Does a high peripheral monocyte count predict future heart failure-related events in patients with chronic heart failure?
Cohort (n=678)
No
Does a high peripheral monocyte count predict future heart failure-related events in patients with chronic heart failure?
Effect estimate: HR 2.24 (95% CI 1.01-4.99)
p-value: p=0.04
High peripheral monocyte count serves as an independent prognostic marker for future heart failure events specifically in patients with non-HFpEF, highlighting distinct pathophysiological mechanisms compared to HFpEF.
Supports distinct monocyte prognostic value by HF phenotype; hypothesis-generating and requires prospective validation before clinical use.
Background: The pathophysiological condition between heart failure (HF) with preserved left ventricular ejection fraction (LVEF; HFpEF) and non-HFpEF is different. To elucidate the prognostic value of monocytes, as representatives of the innate immune system, we examined the association between peripheral monocyte counts and future HF-related events in patients with HF. Methods and Results: in patients with HFpEF. There were 200 patients with non-HFpEF and 478 with HFpEF. Based on receiver operating characteristic analysis, patients with non-HFpEF who were in the high peripheral monocyte group had a significantly higher risk of HF-related events compared with those in the low peripheral monocyte group. In contrast, the high and low peripheral monocyte groups for patients with HFpEF had no significant difference in HF-related events. Multivariate Cox hazard analysis identified high peripheral monocyte counts as an independent and significant predictor of future HF-related events only in patients with non-HFpEF. Conclusions: High peripheral monocyte count was an independent and incremental predictor of HF-related events in non-HFpEF, rather than in patients with HFpEF.
No takes yet. Share an insight, caveat, or question.
Nozuhara et al. (2025) conducted a cohort in Chronic Heart Failure (n=678). High peripheral monocyte count (≥363/mm³ for non-HFpEF) vs. Low peripheral monocyte count was evaluated on Heart failure-related events (hospitalization for HF decompensation) (HR 2.24, 95% CI 1.01-4.99, p=0.04). High peripheral monocyte counts independently predicted future heart failure-related events in patients with non-HFpEF (HR 2.24), but not in patients with HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: